Keith Katkin
CIK 1314596 · PEO;CEO/Urovant Sciences, Inc. · last filed 2026-05-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.04M
Companies
7
Total Filings
87
Lifetime Open-Market Net
-$11.70M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EBS | Director | 111,775 | $8.32 | $930.0K | -$177.6K | 6 | 2026-05-04 |
| SNDX | Director | 124,000 | $18.25 | $2.26M | -$786.1K | 15 | 2026-02-06 |
| ELDN | Director | 8,575 | $3.57 | $30.6K | $0 | 5 | 2026-01-16 |
| RIGL | Director | 25,000 | $32.85 | $821.2K | $0 | 7 | 2021-05-21 |
| Eledon Pharmaceuticals, Inc. (NVUS) Delisted | Director | — | — | — | $0 | 4 | 2020-09-15 |
| Urovant Sciences Ltd. (UROV) Delisted | PEO;CEO/Urovant Sciences, Inc. | 274,892 | $16.24 | $4.46M | -$1.53M | 7 | 2020-02-21 |
| AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | President and CEO | 914,249 | — | — | -$9.20M | 42 | 2014-12-18 |
Recent Filings · Page 6 of 9
87 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-02-14 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Grant (A) | +354,375 | $0 | EDGAR |
| 2013-12-20 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Sell (S) | −29,515 | -$78.9K | EDGAR |
| 2013-12-17 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-11-05 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Sell (S) | −4,385 | -$18.1K | EDGAR |
| 2013-08-02 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Sell (S) | −15,500 | -$75.0K | EDGAR |
| 2013-05-17 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Mixed | −35,000 | -$646.3K | EDGAR |
| 2012-12-19 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Mixed | +410,625 | $138.0K | EDGAR |
| 2012-12-05 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Sell (S) | −18,250 | -$46.5K | EDGAR |
| 2012-06-27 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Sell (S) | −190,125 | -$664.8K | EDGAR |
| 2012-03-07 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Buy (P) | +10,000 | $26.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.